Efficacy and safety of docetaxel chemotherapy combine with 3-dimensional conformal radiation therapy in treatment of esophageal cancer: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

LIU Jingjing ¹ , LU Jiaju ¹ , SHI Jiang ¹ , LIN Qinglin ² , GUO Hong ² , TIAN Jinhui ³ ,  LIU Jian ² , YANG Kehu ³

1. The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, P.R.China;
2. Department of ICU, The First Hospital of Lanzhou University, Lanzhou, 73000, P.R.China;
3. Evidence-Based Medicine Center of Lanzhou University, Lanzhou, 73000, P.R.China;

Corresponding author：

LIU Jian, Email: medecinliu@sina.com

Keywords：

Docetaxel; 3D-CRT; Esophagus cancer; Randomized controlled trial; Meta-analysis; Systematic review

DOI：

10.7507/1672-2531.201703088

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo systematically review efficacy and safety of docetaxel chemotherapy combine with 3-dimensional conformal radiation therapy (3D-CRT) in treatment of esophageal cancer.MethodsDatabases including PubMed, EMbase, The Cochrane Library, Web of Science, CNKI and WanFang Data were searched from inception to February 2017 to collect randomized controlled trials (RCTs) and quasi-randomized control trials (qRCTs) about docetaxel chemotherapy combine with 3D-CRT in treatment of esophageal cancer. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed by using Stata 12.0 software.ResultsA total of 17 RCTs involving 1 353 patients were included. The results of meta-analysis showed that, compared with the radiotherapy alone, the docetaxel chemotherapy combine with 3D-CRT could improve effective rate (OR=1.25, 95%CI 1.07 to 1.47, P=0.003), 3-year survival rate (OR=1.91, 95%CI 1.19 to 3.06, P=0.006), but there were no significant differences in 1-year survival rate (OR=1.28, 95%CI 0.95 to 1.72, P=0.105), hematologic toxicities (OR=1.13, 95%CI 0.85 to 1.49, P=0.389) and gastrointestinal reactions (OR=1.19, 95%CI 0.90 to 1.57, P=0.181).ConclusionsCompared with radiotherapy alone, docetaxel chemotherapy combine with 3D-CRT can improve the effective rate, 3-year survival rate, but not increase the incidences of adverse effects. Due to limited quantity and quality of the included studies, more high quality studies are needed to verify above conclusion.

Citation： LIU Jingjing, LU Jiaju, SHI Jiang, LIN Qinglin, GUO Hong, TIAN Jinhui, LIU Jian, YANG Kehu. Efficacy and safety of docetaxel chemotherapy combine with 3-dimensional conformal radiation therapy in treatment of esophageal cancer: a systematic review. Chinese Journal of Evidence-Based Medicine, 2017, 17(9): 1029-1036. doi: 10.7507/1672-2531.201703088 Copy

1.	Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
2.	Mocanu A, Bârla R, Hoara P, et al. Current endoscopic methods of radical therapy in early esophageal cancer. J Med Life, 2015, 8(2): 150-156.
3.	Shim HJ, Kim DE, Hwang JE, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol, 2012, 70(5): 683-690.
4.	Fulton B, Spencer CM. Docetaxel. Drugs, 1996, 51(6): 1075-1092.
5.	Yamaguchi S, Ohguri T, Imada H, et al. Multimodal approaches including three-dimensional conformal reirradiation for recurrent or persistent esophageal cancer: preliminary results. J Radiat Res, 2011, 52(52): 812-820.
6.	Wang RH. Froreflux esophagitis to Barrett’s esophagus and esophageal adenocarcinoma. World J Gastroenterol, 2015, 21(17): 5210-5219.
7.	Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Available at: http://handbook. cochrane.org.
8.	谭新劲, 刘晋湘, 任丽, 等. 低剂量每周一次多西他赛同步放疗治疗食管癌的临床疗效. 实用癌症杂志, 2009, 24(4): 388-390.
9.	王华. 多西他赛化疗联合放疗治疗食管癌的疗效分析. 吉林医学, 2016, 37(9): 2273-2274.
10.	宋利. 多西他赛化疗联合放疗治疗食管癌的疗效分析. 中国卫生标准管理, 2016, 7(22): 97-99.
11.	张越栋. 多西他赛化疗联合放疗治疗食管癌疗效的临床分析. 中国实用医药, 2015, 10(13): 209-210.
12.	张建辉. 多西他赛化疗联合放疗治疗食管癌疗效的临床分析. 基层医学论坛, 2016, 20(6): 730-731.
13.	臧晔. 多西他赛化疗联合放疗治疗食管癌临床疗效分析. 亚太传统医药, 2014, 10(7): 124-126.
14.	王青民, 杨敬磊, 张玉萍. 放疗联合多西他赛治疗中晚期食管癌疗效观察. 肿瘤基础与临床, 2013, 26(2): 116-118.
15.	李佳, 戴鹏, 蒋晓东. 多西他赛与调强适形放疗同步治疗食管癌临床疗效观察. 齐齐哈尔医学院学报, 2011, 32(1): 24-25.
16.	胡筱, 马桂香, 蒋文慧, 等. 同步放化疗与单纯放疗对局部晚期食管癌疗效的对比分析. 中国肿瘤外科杂志, 2015, 7(3): 189-191.
17.	丁华, 蔡晶, 谢国栋, 等. 三维适形放疗联合多西他赛同步化疗治疗中晚期食管癌的临床研究. 齐齐哈尔医学院学报, 2010, 31(22): 3546-3547.
18.	熊慧如, 尤传文, 陆锡燕, 等. 多西他赛每周方案联合放疗治疗老年局部晚期食管癌的临床疗效观察. 海南医学, 2013, 24(6): 793-795.
19.	苑仁冰, 徐丽杰, 黄树峰, 等. 多西紫杉醇联合三维适形放疗治疗食管癌的临床疗效观察. 中国伤残医学, 2012, 20(6): 88-89.
20.	姜丽华. 周剂量多西他赛同步放疗治疗食管癌. 肿瘤基础与临床, 2014, 27(4): 306-307.
21.	谷凡. 探讨多西他赛化疗联合放疗治疗食管癌的临床疗效. 中国实用医药, 2015, 10(21): 161-162.
22.	杨常建, 董海林, 聂改红, 等. 多西他赛化疗联合放疗治疗食管癌疗效的系统评价. 世界临床医学, 2016, 10(4): 3-4.
23.	蒋晓东, 于金明, 吴瑾, 等. 多西他赛乏氧增敏放射治疗食管癌的临床研究. 实用肿瘤杂志, 2010, 25(4): 436-440, 441.
24.	郭军辉. 多西他赛化疗联合放疗治疗食管癌疗效的系统评价. 中国保健营养, 2015, 25(9): 275-276.
25.	Bedford JL, Viviers L, Guzel Z, et al. A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Ra-diother Oncol, 2000, 57(2): 183-193.
26.	Kim DE, Kim UJ, Choi WY, et al. Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. Cancer Res Treat, 2013, 45(4): 276-284.
27.	Pasini F, de Manzoni G, Durante E, et al. High pathological response rate in esophageal cancer after neoadjuvant radiotherapy (RT) and concomitant weekly chemotherapy with dose escalating of docetaxel. J Clin Oncol, 2004, 22(14 suppl): 4059.
28.	Feiran L, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol, 2013(8): 1558-1562.
29.	Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer, 2000, 36(13): 1649-1660.
30.	Hennequin C. Association of taxanes and radiotherapy: preclinical and clinical studies. Cancer Radiother, 2004, 8(suppl 1): S95-105.
31.	Hertel H, Kohler C, Michels W, et al. Laparoscopic-assited radical vaginal hysterectomy(LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol, 2003, 90(3): 505-511.

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
2. Mocanu A, Bârla R, Hoara P, et al. Current endoscopic methods of radical therapy in early esophageal cancer. J Med Life, 2015, 8(2): 150-156.
3. Shim HJ, Kim DE, Hwang JE, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol, 2012, 70(5): 683-690.
4. Fulton B, Spencer CM. Docetaxel. Drugs, 1996, 51(6): 1075-1092.
5. Yamaguchi S, Ohguri T, Imada H, et al. Multimodal approaches including three-dimensional conformal reirradiation for recurrent or persistent esophageal cancer: preliminary results. J Radiat Res, 2011, 52(52): 812-820.
6. Wang RH. Froreflux esophagitis to Barrett’s esophagus and esophageal adenocarcinoma. World J Gastroenterol, 2015, 21(17): 5210-5219.
7. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Available at: http://handbook. cochrane.org.
8. 谭新劲, 刘晋湘, 任丽, 等. 低剂量每周一次多西他赛同步放疗治疗食管癌的临床疗效. 实用癌症杂志, 2009, 24(4): 388-390.
9. 王华. 多西他赛化疗联合放疗治疗食管癌的疗效分析. 吉林医学, 2016, 37(9): 2273-2274.
10. 宋利. 多西他赛化疗联合放疗治疗食管癌的疗效分析. 中国卫生标准管理, 2016, 7(22): 97-99.
11. 张越栋. 多西他赛化疗联合放疗治疗食管癌疗效的临床分析. 中国实用医药, 2015, 10(13): 209-210.
12. 张建辉. 多西他赛化疗联合放疗治疗食管癌疗效的临床分析. 基层医学论坛, 2016, 20(6): 730-731.
13. 臧晔. 多西他赛化疗联合放疗治疗食管癌临床疗效分析. 亚太传统医药, 2014, 10(7): 124-126.
14. 王青民, 杨敬磊, 张玉萍. 放疗联合多西他赛治疗中晚期食管癌疗效观察. 肿瘤基础与临床, 2013, 26(2): 116-118.
15. 李佳, 戴鹏, 蒋晓东. 多西他赛与调强适形放疗同步治疗食管癌临床疗效观察. 齐齐哈尔医学院学报, 2011, 32(1): 24-25.
16. 胡筱, 马桂香, 蒋文慧, 等. 同步放化疗与单纯放疗对局部晚期食管癌疗效的对比分析. 中国肿瘤外科杂志, 2015, 7(3): 189-191.
17. 丁华, 蔡晶, 谢国栋, 等. 三维适形放疗联合多西他赛同步化疗治疗中晚期食管癌的临床研究. 齐齐哈尔医学院学报, 2010, 31(22): 3546-3547.
18. 熊慧如, 尤传文, 陆锡燕, 等. 多西他赛每周方案联合放疗治疗老年局部晚期食管癌的临床疗效观察. 海南医学, 2013, 24(6): 793-795.
19. 苑仁冰, 徐丽杰, 黄树峰, 等. 多西紫杉醇联合三维适形放疗治疗食管癌的临床疗效观察. 中国伤残医学, 2012, 20(6): 88-89.
20. 姜丽华. 周剂量多西他赛同步放疗治疗食管癌. 肿瘤基础与临床, 2014, 27(4): 306-307.
21. 谷凡. 探讨多西他赛化疗联合放疗治疗食管癌的临床疗效. 中国实用医药, 2015, 10(21): 161-162.
22. 杨常建, 董海林, 聂改红, 等. 多西他赛化疗联合放疗治疗食管癌疗效的系统评价. 世界临床医学, 2016, 10(4): 3-4.
23. 蒋晓东, 于金明, 吴瑾, 等. 多西他赛乏氧增敏放射治疗食管癌的临床研究. 实用肿瘤杂志, 2010, 25(4): 436-440, 441.
24. 郭军辉. 多西他赛化疗联合放疗治疗食管癌疗效的系统评价. 中国保健营养, 2015, 25(9): 275-276.
25. Bedford JL, Viviers L, Guzel Z, et al. A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Ra-diother Oncol, 2000, 57(2): 183-193.
26. Kim DE, Kim UJ, Choi WY, et al. Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. Cancer Res Treat, 2013, 45(4): 276-284.
27. Pasini F, de Manzoni G, Durante E, et al. High pathological response rate in esophageal cancer after neoadjuvant radiotherapy (RT) and concomitant weekly chemotherapy with dose escalating of docetaxel. J Clin Oncol, 2004, 22(14 suppl): 4059.
28. Feiran L, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol, 2013(8): 1558-1562.
29. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer, 2000, 36(13): 1649-1660.
30. Hennequin C. Association of taxanes and radiotherapy: preclinical and clinical studies. Cancer Radiother, 2004, 8(suppl 1): S95-105.
31. Hertel H, Kohler C, Michels W, et al. Laparoscopic-assited radical vaginal hysterectomy(LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol, 2003, 90(3): 505-511.

Previous Article
Correlation of pSTAT3 overexpression and prognosis in lung cancer patients: a meta-analysis
Next Article
Influence of doula delivery on postpartum depression in puerperae: a meta-analysis

Chinese Journal of Evidence-Based Medicine

Efficacy and safety of docetaxel chemotherapy combine with 3-dimensional conformal radiation therapy in treatment of esophageal cancer: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content